{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:27:34Z","timestamp":1761488854134},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,2,8]],"date-time":"2012-02-08T00:00:00Z","timestamp":1328659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2334-12-35","type":"journal-article","created":{"date-parts":[[2012,2,8]],"date-time":"2012-02-08T13:20:24Z","timestamp":1328707224000},"source":"Crossref","is-referenced-by-count":36,"title":["Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands"],"prefix":"10.1186","volume":"12","author":[{"given":"Patricia","family":"Kaaijk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arie","family":"van der Ende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Berbers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germie PJM","family":"van den Dobbelsteen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nynke Y","family":"Rots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,8]]},"reference":[{"key":"1718_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4161\/hv.7.2.13717","volume":"7","author":"R Gasparini","year":"2011","unstructured":"Gasparini R, Panatto D: Meningococcal glycoconjugate vaccines. Hum Vaccin. 2011, 7: 170-182. 10.4161\/hv.7.2.13717.","journal-title":"Hum Vaccin"},{"key":"1718_CR2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/B978-1-4160-3611-1.50023-4","volume-title":"Vaccines","author":"DM Granoff","year":"2008","unstructured":"Granoff DM, Harrison LH, Borrow R: Meningococcal vaccines. Vaccines. Edited by: Plotkin SA, Orenstein WA, Offit PA. 2008, Saunders, Elsevier, 399-434. 5","edition":"5"},{"key":"1718_CR3","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/j.1651-2227.2010.01908.x","volume":"99","author":"E Chiappini","year":"2010","unstructured":"Chiappini E, Venturini E, Bonsignori F, Galli L, de Martino M: Serogroup C Neisseria meningitidis invasive infection: analysis of the possible vaccination strategies for a mass campaign. Acta Paediatr. 2010, 99: 1609-1614. 10.1111\/j.1651-2227.2010.01908.x.","journal-title":"Acta Paediatr"},{"key":"1718_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1574-6976.2006.00053.x","volume":"31","author":"CL Trotter","year":"2007","unstructured":"Trotter CL, Ramsay ME: Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2007, 31: 101-107. 10.1111\/j.1574-6976.2006.00053.x.","journal-title":"FEMS Microbiol Rev"},{"key":"1718_CR5","unstructured":"Bacterial Meningitis in the Netherlands. Annual reports 2000-2009. [ http:\/\/www.amc.uva.nl\/?pid=8446 ]"},{"key":"1718_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s10096-008-0535-1","volume":"27","author":"CS de Greeff","year":"2008","unstructured":"de Greeff CS, de Melker HE, Schouls LM, Spanjaard L, van Deuren M: Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 20032005. Eur J Clin Microbiol Infect Dis. 2008, 27: 985-992. 10.1007\/s10096-008-0535-1.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1718_CR7","volume-title":"RIVM Rapport 210021011 Vaccinatiegraad Rijksvaccinatieprogramma Nederland","author":"EA Lier van","year":"2010","unstructured":"Lier van EA, et al: RIVM Rapport 210021011 Vaccinatiegraad Rijksvaccinatieprogramma Nederland. 2010, [ http:\/\/www.rivm.nl\/bibliotheek\/rapporten\/210021011.pdf ]"},{"key":"1718_CR8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/527401","volume":"197","author":"MC Maiden","year":"2008","unstructured":"Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al: Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008, 197: 737-743. 10.1086\/527401.","journal-title":"J Infect Dis"},{"key":"1718_CR9","doi-asserted-by":"publisher","first-page":"e12144","DOI":"10.1371\/journal.pone.0012144","volume":"5","author":"RM de Voer","year":"2010","unstructured":"de Voer RM, Mollema L, Schepp RM, de Greeff SC, van Gageldonk PG, de Melker HE, et al: Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal C conjugate vaccine. PLoS One. 2010, 5: e12144-10.1371\/journal.pone.0012144.","journal-title":"PLoS One"},{"key":"1718_CR10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1017\/S0950268898001587","volume":"121","author":"HE de Melker","year":"1998","unstructured":"de Melker HE, Conyn-van Spaendonck MA: Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiol Infect. 1998, 121: 637-643. 10.1017\/S0950268898001587.","journal-title":"Epidemiol Infect"},{"key":"1718_CR11","first-page":"301","volume":"67","author":"FR van der Klis","year":"2009","unstructured":"van der Klis FR, Mollema L, Berbers GA, de Melker HE, Coutinho RA: Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med. 2009, 67: 301-308.","journal-title":"Neth J Med"},{"key":"1718_CR12","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","volume":"336","author":"MD Snape","year":"2008","unstructured":"Snape MD, Kelly DF, Lewis S, Banner C, Kibwana L, Moore CE, et al: Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ. 2008, 336: 1487-1491. 10.1136\/bmj.39563.545255.AE.","journal-title":"BMJ"},{"key":"1718_CR13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","volume":"10","author":"N Andrews","year":"2003","unstructured":"Andrews N, Borrow R, Miller E: Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003, 10: 780-786.","journal-title":"Clin Diagn Lab Immunol"},{"key":"1718_CR14","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.4049\/jimmunol.180.4.2165","volume":"180","author":"G Blanchard Rohner","year":"2008","unstructured":"Blanchard Rohner G, Snape MD, Kelly DF, John T, Morant A, Yu LM, et al: The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol. 2008, 180: 2165-2173.","journal-title":"J Immunol"},{"key":"1718_CR15","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1086\/508776","volume":"43","author":"MD Snape","year":"2006","unstructured":"Snape MD, Kelly DF, Salt P, Green S, Snowden C, Diggle L, et al: Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis. 2006, 43: 1387-1394. 10.1086\/508776.","journal-title":"Clin Infect Dis"},{"key":"1718_CR16","doi-asserted-by":"publisher","first-page":"6974","DOI":"10.1016\/j.vaccine.2009.09.082","volume":"27","author":"RM de Voer","year":"2009","unstructured":"de Voer RM, van der Klis FR, Engels CW, Schepp RM, van de Kassteele J, Sanders EA, et al: Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults. Vaccine. 2009, 27: 6974-6982. 10.1016\/j.vaccine.2009.09.082.","journal-title":"Vaccine"},{"key":"1718_CR17","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1128\/IAI.71.10.5549-5555.2003","volume":"71","author":"R Borrow","year":"2003","unstructured":"Borrow R, Goldblatt D, Finn A, Southern J, Ashton L, Andrews N, et al: Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun. 2003, 71: 5549-5555. 10.1128\/IAI.71.10.5549-5555.2003.","journal-title":"Infect Immun"},{"key":"1718_CR18","unstructured":"Joint Committee on Vaccination and Immunisation DoH, England. Proposed changes to the routine childhood immunisation schedule. 2005, [ http:\/\/www.advisorybodies.doh.gov.uk\/jcvi\/childhoodimmunisationoc05.pdf ]"},{"key":"1718_CR19","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1016\/j.vaccine.2006.02.010","volume":"24","author":"P De Wals","year":"2006","unstructured":"De Wals P, Trottier P, P\u00e9pin J: Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation. Vaccine. 2006, 24: 3500-3504. 10.1016\/j.vaccine.2006.02.010.","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"1718_CR20","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jcpa.2007.04.004","volume":"137","author":"CA Siegrist","year":"2007","unstructured":"Siegrist CA: The challenges of vaccine responses in early life: selected examples. J Comp Pathol. 2007, 137 (Suppl 1): S4-9.","journal-title":"J Comp Pathol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-12-35\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-12-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-12-35","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-12-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T22:51:47Z","timestamp":1593643907000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-12-35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,8]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1718"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-12-35","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,8]]},"article-number":"35"}}